Evidence map›Paper›PMID 31611949›Full record

ArticleOncology letters2019

Dauricine suppresses the growth of pancreatic cancer

Ying-Bo Zhang, Hong-Xin Fei, Jia Guo, Xiao-Jie Zhang, Shu-Liang Wu, Li-Li Zhong

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Dauricine: Review of Pharmacological Activity.Drug design, development and therapy · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Ying-Bo ZhangUltramicropathology Experimental Center, Pathology College, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China.
Hong-Xin FeiDepartment of Basic Medicine, School of Nursing and Rehabilitation, Xinyu University, Xinyu, Jiangxi 338004, P.R. China.
Jia GuoPathogenic Biology and Immunology Experimental Teaching Center, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China.
Xiao-Jie ZhangUltramicropathology Experimental Center, Pathology College, Qiqihar Medical University, Qiqihar, Heilongjiang 161006, P.R. China.
Shu-Liang WuDepartment of Anatomy, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
Li-Li ZhongDepartment of Pathology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China.
Qiqihar Medical University · CNFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine · CNHarbin Medical University · CNXinyu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a highly malignant cancer associated with high expression levels of sonic hedgehog signaling molecule (Shh), patched 1 (Ptch1), smoothened frizzled class receptor (Smo) and glioma-associated oncogene family zinc finger 1 (Gli1) in the hedgehog (Hh) signaling pathway. Inhibition of the Hh signaling pathway is a potential therapeutic target for pancreatic cancer. The aim of the present study was to investigate the effects of dauricine in a pancreatic cancer BxPC-3 ×enograft animal model and examine the underlying molecular mechanisms through Hh signaling pathway. High-and low-dose dauricine treatment significantly suppressed tumor growth with no concomitant effect on the spleen index. In addition, dauricine induced apoptosis and cell cycle arrest in pancreatic cancer BxPC-3 cells. The inhibitory effects of dauricine on pancreatic cancer may be mediated by the suppression of the Hh signaling pathway, as indicated by the decreases in the gene and protein expression levels of Shh, Ptch1, Smo and Gli1. The effects of dauricine were similar to those of 5-fluorouracil. Dauricine, a naturally occurring alkaloid, may be a potential anticancer agent for the treatment of pancreatic cancer.

Indexed as

dauricinehedgehog signaling pathwaypancreatic cancer

Identifiers

PMID31611949
PMCPMC6781764
OpenAlexW2972038856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.